RESUMEN
Objectives: Amanita phalloides contains amanitin, inhibiting RNA polymerase II. Partial inhibition with amanitin influences tumor cell - but not normal cell - activity. A patient with diagnosed B-cell chronic lymphatic leukemia was treated successfully for eight years with Amanita phalloides. However, the necessary dose for stabilization of the disease increased during this time. In addition thrombocyte levels decreased, indicating bone marrow affection. Therefore additional regimen was necessary. Methods: Chelidonium majus contains alkaloids with cytostatic and cytotoxic potential. In addition to Amanita, Chelidonium was applied. Results: During treatment with Amanita and Chelidonium, leukocyte levels and lactate-dehydrogenase levels were roughly unaffected, meaning there is no strong effect on tumor growth of cells, and no observable cell destruction. Anyhow, thrombocyte levels increased after the Chelidonium treatment, indicating an effect in the bone marrow. Conclusion: Chelidonium majus can be useful during Amanita therapy as a pulse to regenerate bone marrow affection.
RESUMEN
Background: To date, Chronic Lymphocytic Leukemia (CLL) has been viewed as a malignant disease with tumor growth of cells. This hypothesis should be reviewed. Methods: A patient diagnosed with CLL is treated with Amanita phalloides, containing amanitin, inhibiting specifically tumor cell activity without affecting normal cells. Despite initial leukocyte cell count decrease, further therapy fails after eight months. He suffers from severe symptoms of inflammation, not specific for CLL. Additional Borrelia infection is diagnosed and Terebinthina laricina is applied. Results: Herxheimer reaction occurs some weeks later, accompanied by continuous leukocyte cell count drop to normal range within four months, even after stopping Amanita therapy. All symptoms of borreliosis and CLL vanished. Conclusion: CLL might be induced by a Borrelia-infection. This should be considered in diagnostic and therapeutic regimen.